AR095707A1 - Derivados de piperazina como inhibidores de fasn - Google Patents

Derivados de piperazina como inhibidores de fasn

Info

Publication number
AR095707A1
AR095707A1 ARP140101320A ARP140101320A AR095707A1 AR 095707 A1 AR095707 A1 AR 095707A1 AR P140101320 A ARP140101320 A AR P140101320A AR P140101320 A ARP140101320 A AR P140101320A AR 095707 A1 AR095707 A1 AR 095707A1
Authority
AR
Argentina
Prior art keywords
denotes
atoms
hal
branched
alkyl
Prior art date
Application number
ARP140101320A
Other languages
English (en)
Spanish (es)
Inventor
Dr Staehle Wolfgang
Dr Friese-Hamim Manja
Dr Tsaklakidis Christos
Dr Wienke Dirk
Dr Leuthner Birgitta
Original Assignee
Merck Patent Ges Mit Beschränkter Haftung
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47912880&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR095707(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Patent Ges Mit Beschränkter Haftung filed Critical Merck Patent Ges Mit Beschränkter Haftung
Publication of AR095707A1 publication Critical patent/AR095707A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/02Suppositories; Bougies; Bases therefor; Ovules
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/08Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with a hetero atom directly attached to the ring nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24Oxygen atoms
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
ARP140101320A 2013-03-21 2014-03-21 Derivados de piperazina como inhibidores de fasn AR095707A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP13001462 2013-03-21

Publications (1)

Publication Number Publication Date
AR095707A1 true AR095707A1 (es) 2015-11-04

Family

ID=47912880

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP140101320A AR095707A1 (es) 2013-03-21 2014-03-21 Derivados de piperazina como inhibidores de fasn

Country Status (10)

Country Link
US (1) US9809552B2 (enExample)
EP (1) EP2976328B2 (enExample)
JP (2) JP6412553B2 (enExample)
CN (1) CN105008329B (enExample)
AR (1) AR095707A1 (enExample)
AU (1) AU2014234721A1 (enExample)
CA (1) CA2907657A1 (enExample)
ES (1) ES2634875T3 (enExample)
IL (1) IL241513A0 (enExample)
WO (1) WO2014146747A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112521369A (zh) 2013-03-13 2021-03-19 福马治疗股份有限公司 用于抑制fasn的化合物及组合物
CN107847765B (zh) 2015-06-18 2021-05-04 89生物有限公司 1,4-取代的哌啶衍生物
EP3310773B1 (en) 2015-06-18 2020-12-02 89Bio Ltd. Substituted 4-benzyl and 4-benzoyl piperidine derivatives
DK3458448T3 (da) 2016-04-25 2021-08-23 Forma Therapeutics Inc Fasn-inhibitorer til anvendelse til behandling af non-alkoholisk steatohepatitis
TWI767148B (zh) 2018-10-10 2022-06-11 美商弗瑪治療公司 抑制脂肪酸合成酶(fasn)
WO2020092395A1 (en) 2018-10-29 2020-05-07 Forma Therapeutics, Inc. SOLID FORMS OF (4-(2-FLUORO-4-(1-METHYL-1 H-BENZO[d]IMIDAZOL-5-YL)BENZOYL) PIPERAZIN-1-YL)(1-HYDROXYCYCLOPROPYL)METHANONE
CN117658948A (zh) * 2023-12-14 2024-03-08 辽宁省人民医院 Fasn小分子抑制剂的筛选及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19743435A1 (de) 1997-10-01 1999-04-08 Merck Patent Gmbh Benzamidinderivate
DE102007007751A1 (de) * 2007-02-16 2008-08-21 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue substituierte Arylsulfonylglycine, deren Herstellung und deren Verwendung als Arzneimittel
EP2247600A4 (en) 2008-02-06 2011-09-14 Biomarin Pharm Inc INHIBITORS BASED ON BENZOXAZOLE-CARBOXAMIDE COMPOUNDS OF POLY (ADP-RIBOSE) POLYMERASE (PARP) ACTIVITY
JP5744886B2 (ja) * 2009-10-19 2015-07-08 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング シクロペンタンカルボキサミド誘導体、このような化合物を含む薬物及びそれらの使用
KR101261702B1 (ko) * 2011-01-07 2013-05-06 이화여자대학교 산학협력단 신규한 2-페닐퀴나졸린-4(3h)-온 유도체, 그 제조방법 및 그 약학적 조성물
CN102627610B (zh) * 2012-04-11 2014-06-25 江苏先声药物研究有限公司 一类苯并咪唑类衍生物及其应用
CN112521369A (zh) 2013-03-13 2021-03-19 福马治疗股份有限公司 用于抑制fasn的化合物及组合物

Also Published As

Publication number Publication date
CA2907657A1 (en) 2014-09-25
JP6412553B2 (ja) 2018-10-24
ES2634875T3 (es) 2017-09-29
US20160280655A1 (en) 2016-09-29
EP2976328A1 (en) 2016-01-27
AU2014234721A1 (en) 2015-11-05
EP2976328B1 (en) 2017-05-03
CN105008329A (zh) 2015-10-28
US9809552B2 (en) 2017-11-07
CN105008329B (zh) 2018-01-05
WO2014146747A1 (en) 2014-09-25
JP2018188452A (ja) 2018-11-29
IL241513A0 (en) 2015-11-30
EP2976328B2 (en) 2019-07-03
JP2016515550A (ja) 2016-05-30

Similar Documents

Publication Publication Date Title
AR095707A1 (es) Derivados de piperazina como inhibidores de fasn
AR092211A1 (es) Derivados de hidropirrolopirrol
AR096235A1 (es) Arilquinazolinas
AR089944A1 (es) Derivados de tetrahidro-quinazolinona
AR092670A1 (es) Derivados de quinazolinona
PE20210667A1 (es) Derivados de benzamida para la inhibicion de la actividad abl1, abl2 y bcr-abl1
AR097086A1 (es) Derivados 1,3-disustituidos de ciclopentano
AR081628A1 (es) 5-fluoro-1h-pirazolopiridinas sustituidas y su uso
AR098136A1 (es) Compuestos de heteroarilo como inhibidores de btk y usos de los mismos
AR096979A1 (es) Derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
AR092270A1 (es) Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b
MX367713B (es) Uso de derivados de pirazolopirimidina para el tratamiento de trastornos relacionados con la fosfoinositida 3-cinasa delta.
AR106763A1 (es) Oxadiazoles sustituidos para combatir hongos fitopatógenos
AR096684A1 (es) Compuestos para tratar atrofia muscular espinal
AR106595A1 (es) COMPUESTOS HETEROCÍCLICOS COMO INHIBIDORES DE PI3K-g
AR100137A1 (es) Compuestos 4-amino-imidazoquinolina
NI201500120A (es) Compuestos de biaril - amida como inhibidores de cinasa
AR090589A1 (es) INHIBIDORES DE b-LACTAMASA ISOXAZOL
AR093036A1 (es) Derivados de pirrolotriazinona como inhibidores de pi3k
CL2016003301A1 (es) Compuestos derivados del ácido amino-(piridin-4-carboxílico) sustituidos, inhibidores de la histona desmetilasa; composición farmacéutica, que los comprende, útiles en el tratamiento del cáncer, tales como el cáncer de próstata, mama, vejiga, pulmón y/o melanoma.
AR106053A1 (es) Compuestos imidazo[4,5-c]quinolin-2-ona y su uso para el tratamiento del cáncer
CR20180316A (es) Derivados de dihidroimidazopirazinona usados en el tratamiento del cáncer
AR100333A1 (es) Derivados de heterociclil-butanamida
AR089945A1 (es) DERIVADOS DE FURO[3,2-B] Y TIENO[3,2-B]PIRIDINA COMO MODULADORES DE TBK1 E IKKe
UY35419A (es) Inhibidores de cdk9 quinasa de pirrolo (2,3- b) piridina

Legal Events

Date Code Title Description
FB Suspension of granting procedure